CLONING OF HUMAN TUMOR CELLS IN TISSUE CULTURE SYSTEMS

组织培养系统中人类肿瘤细胞的克隆

• 批准号: 3615208
• 负责人: MARTIN J MURPHY
• 金额: $ 24.94万
• 依托单位: HIPPLE CANCER RESEARCH CORPORATION
• 依托单位国家: 美国
• 财政年份: 1987
• 资助国家: 美国
• 起止时间: 1987-09-30 至 1989-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3615208
• 关键词: antineoplastic antibiotics; bioassay; biopsy; biotechnology; breast neoplasms; carcinoma; clone cells; dosage; drug hypersensitivity; drug screening /evaluation; human subject; neoplasm /cancer chemotherapy; neoplasm /cancer remission /regression; neoplastic cell; neoplastic growth; radiotracer; tritium

Having demonstrated the feasibility of the capillary tumor clonogenic cell assay in Phase I, the initial effort of the Phase II contract will be the optimization and evaluation of this system, the application of this assay to the study of the growth kinetics of colonies grown in the capillary tubes, the feasibility of a radioisotope endpoint for this system, and the determination of the stability of selected anti-cancer drugs - under the assay conditions - in this system. This having been accomplished, in collaboration with consultants, this system will be used in a prospective clinical correlation of patients' response to chemotherapy and the in vitro sensitivity of their tumors as determine by this assay. Patients entered into this study will be followed for a period of two years - by the consultants - in order to evaluate the predictability of this assay with the selection of the anti-neoplastic agent and patient response. Finally, the application of this assay as a tool for the screening of potential new anti-neoplastic agents will be studied.

论证了毛细血管肿瘤的可行性 克隆细胞检测的第一阶段，第二阶段的初步努力 合同将是对这一系统的优化和评估， 该方法在细菌生长动力学研究中的应用 在毛细管中生长的菌落，一种 这一系统的放射性同位素终点，以及 选定的抗癌药物的稳定性-在测试下 条件--在这个系统中。这已经完成了，在 与顾问合作，该系统将用于 患者对药物治疗反应的前瞻性临床相关性 化疗与肿瘤体外敏感性的关系 通过这一化验来确定。进入这项研究的患者将是 在两年的时间里--由顾问--按照 为了评估这一检测方法的可预测性，选择 抗肿瘤药物和患者反应。最后， 该检测方法在潜在致病基因筛选中的应用 将研究新的抗肿瘤药物。